1. Scrip
  3. >>Cardiovascular

Neuroprotection in stroke: worth another crack?

 
• By Alexandra Shimmings

Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise for a protein acting on a post-synaptic brain protein. Together with some promising early data for two other potential neuroprotective agents, experts say the data seem to support renewed efforts in developing such drugs despite their chequered developmental history.

Hopes that a neuroprotective agent can be developed to reduce the damage caused by ischaemic stroke have received a boost, with data from a Phase II trial in the The Lancet Neurology showing promise for a protein acting on a post-synaptic brain protein. Together with some promising early data for two other potential neuroprotective agents, experts say the data seem to support renewed efforts in developing such drugs despite their chequered developmental history.

The latest product, NA-1, is in development by two private companies, Arbor Vita in the US and NoNO of Canada,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 
• By Andrew McConaghie

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 
• By Andrew McConaghie

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

More from Therapy Areas

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.